Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025

生物学的製剤API(原薬)製造サービスの世界市場

◆タイトル:Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025
◆商品コード:VGAIN5072209
◆調査・発行会社:visiongain
◆発行日:2015年7月
◆ページ数:207
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥259,056見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥431,856見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥719,856見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、生物学的製剤API(原薬)製造サービスの世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・生物学的製剤API(原薬)製造サービスの世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・生物学的製剤API(原薬)製造サービスの世界市場:セグメント別市場分析
・地域別市場分析、市場規模予測
・主な医薬品製造受託機関(CMO)分析
・市場環境分析
・市場動向:定性分析
・専門家の見解
・主要企業分析
・結論

Outsourced Biopharma Production – New Analysis Showing You Revenue Forecasts
What is the outlook for making biological active pharma ingredients (APIs) under contract? Visiongain’s new report predicts those revenues from 2015. There you see financial data, also assessing trends, technologies, clients’ needs and opportunities.

Our study gives you sales forecasts to 2025 at overall world market, submarket and national level. Discover what’s happening for those production services – outsourcing and off-shoring for biological drugs (biologics). That way you gain in knowledge, also helping your influence.

Please read on to explore that industry and see what future revenue it could generate.

Sales forecasts and discussions to help your research, analyses and decisions
Our study shows you what the future holds for those pharma contract manufacturing organisations (CMOs). You see technological and commercial outlooks for producing medicinal components of biologics. And you discover trends to watch.

Besides revenue forecasting to 2025, our new work shows you recent results, growth rates and market shares. There you find original analysis, exploring trends and developments. You gain 57 tables, 49 charts and two interviews with biopharmaceutical companies.

Gains through analysing those drug-making services – advantages for your work
Why miss information you need? Why struggle to find data? Instead let our analysis guide you through that outsourcing industry’s present and future. Your search has just become easier.

Discover where trends in that pharma service industry lead, exploring where the money lies, finding the most lucrative opportunities.

Although no study answers every question, the following sections show how our new investigation benefits your work.

Revenues for the world outsourced biological API market and submarkets
What are the secrets of that industry’s progress? You explore the future of the overall world market for outsourcing that biopharma production.

First our report shows you individual revenue forecasting for three main submarkets to 2025, at world level, with discussions:
• Mammalian cell cultures
• Microbial fermentations (culturing)
• Other biotechnological (expression) systems for yielding medical products.

For API revenues, our study breaks its overall world revenue forecast to 2025 into these five therapeutic classes:
• Monoclonal antibodies (mAbs)
• Insulin
• Vaccines
• Interferons
• Human growth hormones.

That work explains what stimulates and restrains the biotech API industry, also showing you revenue trends and growth possible. You identify potentials and competition for companies providing those technologies and services to help pharmaceutical companies.

So avoid falling behind, missing business or losing influence. Instead discover how you can benefit by better understanding trends and opportunities from 2015 in that CMO industry.

Our study also gives you geographical revenue predictions for those services.

National markets – what outlooks for production needs and CMOs serving biopharma?
You discover individual revenue forecasts to 2025 for 14 national markets:
• United States (US)
• Germany, France, UK, Italy, Spain (EU5 group) and Switzerland
• Japan
• Brazil, Russia, India and China (BRIC nations)
• South Korea
• Singapore.

For pharma service providers and their customers, many opportunities exist in developed and developing countries. Rising sales of novel biological drugs and biosimilars stimulate demands for outsourced producing of biologics.

There discover how you and your organisation can gain. You find needs and outlooks. Our work explains, also discussing issues affecting that outsourcing of bioproduction.

Developments, challenges and opportunities affecting producers of biological APIs
Our study explains forces affecting that industry and market from 2015, including these influences:
• Services in greatest demand for biopharma CMOs
• Development and proliferation of cell lines and expression systems, including emerging technologies
• Therapies in development (R&D) providing outsourcing opportunity for API makers
• Challenges in making vaccines and other complex protein-based and recombinant medicines
• Improving yields and efficiency in biopharmaceutical operations, including effects on downstream processing.

You also explore these aspects of the biologicals API market and industry:
• Next-generation antibody development, including antibody-drug conjugates (ADCs)
• Orphan drugs and personalised medicines – satisfying specialist production needs
• Single-use bioreactors (disposable systems) for API manufacturers
• Risks of overcapacity for biotechnological CMOs
• Regulations (GMP and other standards) affecting that biopharmaceutical contracting.

There you investigate political, economic, social and technological questions, assessing outlooks for trade. You explore forces shaping that medical business, influencing its success.

Leading companies and 2019 market value – what success is possible?
Our report predicts the world market for producing those therapeutic agents will reach $5.78bn in 2019, expanding fast from 2015 to 2025.

That analysis also shows you what organisations hold most potential. Companies our report profiles include these:
• Boehringer Ingelheim BioXcellence
• Celltrion
• DSM Biologics
• Lonza
• Samsung BioLogics
• FUJIFILM Diosynth Biotechnologies.

【レポートの目次】

1. Report Overview
1.1 Contract Biotech API Manufacturing: World Market Review 2015
1.2 Benefits of this Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by This Analytical Report
1.3 Who is This Study For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Some Associated Reports
1.7 About Visiongain

2. Introduction to Biotech API Manufacturing Services
2.1 What are Biotech API Manufacturing Services?
2.1.1 Producing Biotech API: An Overview of the Manufacturing Process
2.1.2 Defining the Biotech API Manufacturing Market
2.1.3 Differing Expression Systems to Manufacture APIs
2.2 Challenges in Manufacturing Biotech API
2.3 Outsourcing: A Common Trend in Biotech API Manufacturing Services
2.4 Future Trends for the Biotech API Manufacturing Services Market
2.5 Glossary

3. Biotech API Manufacturing Services: World Market Outlook and Forecast 2015-2025
3.1 The Contract Biotech API Manufacturing Services Market Performance, 2014
3.1.1 Contract Biotech API Manufacturing Services: Forecast 2015-2025
3.2 Drivers and Restraints in the Biotech API Manufacturing Services Market
3.2.1 Important Drivers in the Biotech API Manufacturing Services Market for the Coming Decade
3.2.1.1 The Ageing Population is a Driver for Growth
3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
3.2.1.3 Outsourcing as a Driver for Growth
3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
3.2.1.5 Increased Investment in Orphan Drugs from Companies
3.2.1.6 Emerging Markets Will Grow and Influence the Market
3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
3.2.2 Restraints on Growth in the Biotech API Manufacturing Services Market
3.2.2.1 Pricing Pressures Will Limit Market Growth
3.2.2.2 Regulatory Restrictions Will Increase
3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
3.2.2.4 Complexity of API Production is a Challenge
3.3 Outlook for the Outsourced Biotech API Services: Increased Demand

4. Biotech API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2015-2025
4.1 Submarkets for the Biotech API Manufacturing Services Industry
4.1.1 The Mammalian Cell Culture Submarket
4.1.2 The Mammalian Cell Culture Submarket Forecast 2015-2025
4.1.3 ADCs and Next-Generation Antibodies Will Drive Growth 2015-2025
4.1.4 The Microbial Fermentation Submarket
4.1.5 The Microbial Fermentation Submarket Forecast 2015-2025
4.1.5.1 Increase in Demand for Insulin Will Drive Growth 2015-2025
4.1.6 Other APIs Expression Systems Are Still in Development
4.1.6.1 Plant-Made Pharmaceuticals
4.1.6.2 Yeast Cell Expression Systems
4.1.6.3 Insect Cell Expression Systems
4.1.6.4 Other Expression Systems Submarket Forecast 2015-2025
4.2 Chapter Summary: Positive Growth for the Market

5. Biotech API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors, 2015-2025
5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2015-2025
5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
5.2.1 Contract API Vaccine Market: Outlook and Forecast 2015-2025
5.2.2 Challenges in Manufacturing Vaccines
5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
5.3.1 Contract API Insulin Analogues Forecast 2015-2025
5.3.2 Insulin Analogues: In-House Production Restrains the Contract API Insulin Therapies Market Growth
5.3.3 Development Trends in the Contract API Insulin Market to 2025
5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
5.4.1 Contract API Interferon Market Forecast 2015-2025
5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
5.5.1 Contract API Growth Hormone Market Forecast 2015 to 2025
5.5.2 Most Manufacturing is In-House for Growth Hormone Production
5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
5.6 Chapter Summary: Outsourcing for Key Biological Products 2015-2025

6. Leading National Markets for Contract Biotech API Manufacturing Services, 2015-2025
6.1 Regional Breakdown of the World Biotech API Manufacturing Services Market
6.1.1 US and EU Dominate Growth for Leading National Submarkets 2015-2025
6.1.2 National Revenue Shares by 2025: Emerging Market Growth
6.2 Contract Biotech API Manufacturing in Europe 2015-2025
6.2.1 Strong Growth for the EU Revenue Forecasts 2015-2025
6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2015-2025
6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
6.2.2.3 France: Strong Vaccine Development Industry
6.2.2.4 Switzerland: Headquarters for Leading Companies
6.2.2.5 Spain: Numerous Biotech Companies
6.2.2.6 Italy: Outlook and Forecast 2015-2025
6.2.3 US: A Market Leader in Biotech API Manufacturing
6.2.4 Japan: A Less Mature Contract Manufacturing Market
6.2.5 BRIC Market: Outlook and Forecasts for Emerging Markets 2015-2025
6.2.5.1 Emerging Nations May Develop a Presence in the Biologics Market
6.2.5.2 Increased Demand for Biosimilars and Biological Drugs 2015-2025
6.2.5.3 China is Poised for Growth: Forecast for 2015-2025
6.2.5.4 India Offers a Lower-Cost Advantage for Biotech API Manufacturing Services: Forecast 2015-2025
6.2.5.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
6.2.5.6 Russian Biotech API Manufacturing Services Forecast: 2015-2025
6.2.5.7 Brazilian Biotech API Manufacturing Services Forecast: 2015-2025
6.2.6 South Korea: Market Forecast, 2015-2025
6.2.6.1 Leading CMOs Celltrion and Samsung BioLogics Drive the Market
6.2.7 Singapore: Market Forecast, 2015-2025
6.3 Summary of Chapter: Outlook for Leading National Submarkets, 2015-2025

7. Leading CMOs in the Biotech API Manufacturing Services Market, 2014
7.1 Four Companies Led the Market in 2014
7.2 Leading Companies by Capacity
7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
7.2.2 Barriers to Market Entry 2015-2025
7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
7.3 FDA Opens Barriers for the Biosimilars Market
7.4 Boehringer Ingelheim BioXcellence
7.4.1 Strategic Outlook: Expanding into the Asian Market
7.5 Celltrion: Biologics Leader in Asia
7.5.1 Celltrion: Likely Target for Mergers and Acquisitions?
7.6 DSM Biologics: Strategically Increasing Capacity
7.7 Lonza Has the Largest Worldwide Cell Culture Capacity
7.7.1 Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
7.8 Other Market Players of Interest in 2014
7.8.1 Samsung BioLogics: Focusing on Biosimilars
7.8.2 Cytovance Biologics: Plans to Expand
7.8.3 Fujifilm Diosynth Biotechnologies
7.8.3.1 Facility and Service Expansion for the Future
7.9 Leading Biopharma Companies Operate CMO Divisions
7.9.1 AbbVie Contract Manufacturing: Strength through Acquisition
7.9.2 GSK Biopharmaceuticals
7.9.3 Sandoz: Expertise in Biologics and Biosimilars
7.9.4 Rentschler Biotechnologie: Recent Expansions
7.10 Teva: A Future Player in the Biologics Market
7.11 Catalent Offers a New Platform through Partnership
7.12 Chapter Summary: Leading Companies, 2015-2025

8. Biotech API Manufacturing Services Market Industry Trends, 2015-2025: Qualitative Analysis
8.1 SWOT Analysis: Strengths and Weaknesses of the Biotech API Manufacturing Services Market, 2014
8.1.1 Biopharmaceutical Demand for Outsourcing is Increasing
8.1.2 A Fragmented Market with a Costly and Difficult Manufacturing Process
8.2 Opportunities for the Biotech API Manufacturing Services Market 2015-2025
8.3 Threats for the Biotech API Manufacturing Services Market 2015-2025
8.4 STEP Analysis of the Biotech API Manufacturing Services Market
8.4.1 Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
8.4.2 Technological Factors: Advances Will Drive Growth
8.4.2.1 Single-Use Technology: A Vital Trend for the Future
8.4.3 Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
8.4.4 Political Factors: Regulatory Requirements Need to Be Met
8.5 Trends in Biological Drug Development 2015-2025
8.5.1 Biosimilars Will Be an Important Opportunity for CMOs
8.5.2 CMOs are Investing in Next-Generation Antibody Development
8.5.3 Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
8.5.4 Outlook for Single-Use Technologies in Biotech API Manufacturing 2015-2025
8.5.4.1 Future Direction: Single-Use Systems Will be Essential
8.5.5 Outsourcing Trends for Biotech API Manufacturing 2015-2025
8.5.5.1 Biopharma Companies Continue to Invest in In-House Facilities
8.5.5.2 Offshoring Biotech API Manufacturing to Emerging Markets: Not a Trend for this Decade?
8.5.5.3 Overcapacity is a Risk for the Biotech CMO Industry
8.5.5.4 Future Trends: Strategic Partnering
8.5.5.5 Alternative Expression Methods
8.6 Regulations and Effects on the Biotech API Manufacturing Services Industry
8.6.1 Effect on the Emerging Biotech API Manufacturing Services Market 2015-2025
8.6.2 Regulations in Other Countries in the Biotech API Market
8.7 Chapter Summary: Industry Trends for Contract Biotech API Manufacturing to 2025

9. Research Interviews
9.1 Interview with Mr Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies
9.1.1 Novel Expression Platforms
9.1.2 Expanding Manufacturing Capacity
9.1.3 Acquisition of Kalon Biotherapeutics – Effects on Business?
9.1.4 Over-capacity – A Realistic Threat to API Manufacturing CMOS?
9.1.5 Future Opportunities for the API Manufacturing CMO Market
9.2 Interview with Mr Jon S. Gingrich, Manager, Business Development, Avid Bioservices Inc., California, USA
9.2.1 Avid Bioservices
9.2.2 The Influence of Biosimilars on the Current Biotech API Manufacturing Services Market for CMOs
9.2.3 Competition in the US Biotech API Manufacturing Services Market
9.2.4 The Challenges of API Manufacturing
9.2.5 Avid Bioservices Strategies for Growth in the Biotech API Manufacturing Services Market

10. Conclusions
10.1 The Contract Biotech API Manufacturing Services Market
10.2 Outlook for the Biotech API Manufacturing Services Market
10.2.1Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biotech API Manufacturing
10.2.2 The US and EU Markets Lead for the Global Biotech API Manufacturing Services Market in 2014-2015
10.2.3 Single-Use Technology Will Become Indispensable for Success in the Market
10.3 Growth in the Market 2014-2025
10.3.1 The Future of the Biotech API Manufacturing Services Marketplace

List of Tables
Table 2.1 Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2013
Table 3.1 Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), 2014-2025
Table 4.1 Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), 2014-2025
Table 4.2 ADCs in Phase II and III Development, 2014
Table 4.3 Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), 2014-2025
Table 4.4 Selected CMOs Investing in ADC Manufacturing Capacity, 2015
Table 4.5 Microbial Fermentation Submarket: API Revenue Forecast ($bn), 2014-2025
Table 4.6 Other Expression Systems Submarket: Two Year Forecast Revenue ($bn), 2015-2025
Table 5.1 Eight Biologic Best-Selling Drugs of 2014
Table 5.2 Contract API Biological Drug Revenue Forecasts by Therapeutic Area ($bn), 2014-2019
Table 5.3 Contract API Biological Drug Revenue Forecasts by Therapeutic Area ($bn), 2020-2025
Table 5.4 Monoclonal Antibody Types and Sources
Table 5.5 Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), 2014-2025
Table 5.6 The Four Classes of Next- Generation Antibody Therapies
Table 5.7 Vaccines Market: Contract API Revenue Forecast ($bn), 2014-2025
Table 5.8 Insulin Therapies Market: Contract API Revenue Forecast ($bn), 2014-2025
Table 5.9 Interferon Therapies Market: Contract API Revenue Forecast ($bn), 2014-2025
Table 5.10 Growth Hormones Market: Contract API Revenue Forecast ($bn), 2014-2025
Table 5.11 Selected Long-Acting Growth Hormones in Development, 2014
Table 6.1 Contract Biotech API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2014
Table 6.2 Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), 2014-2019
Table 6.3 Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), 2020-2025
Table 6.4 Contract Biotech API Manufacturing Market: National Revenue Two Year Shares (%), 2013-2025
Table 6.5 EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), 2015-2025
Table 6.6 EU and Switzerland Contract Biotech API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2014
Table 6.7 German Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.8 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.9 French Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.10 Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.11 Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.12 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.13 US Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.14 Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.15 Contract Biotech API Manufacturing Market: Emerging National Revenue Forecast ($bn), 2015-2025
Table 6.16 Emerging Biologics Markets: API Revenues ($bn) and Market Shares (%), 2014
Table 6.17 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.18 Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.19 Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.20 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.21 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 6.22 Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2015
Table 6.23 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Table 7.1 Leading Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
Table 7.2 Selected Other Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
Table 7.3 Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2015
Table 7.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2013-2014
Table 7.5 Celltrion: Revenue ($bn), 2009-2014
Table 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), 2009-2014
Table 7.7 Lonza: New Biological Drug Sector Manufacturing Agreements, 2014
Table 7.8 Sandoz Biosimilar Pipelines: Selected Biosimilars, 2015
Table 8.1 Contract Biotech API Manufacturing Market: Strengths and Weaknesses, 2014-2015
Table 8.2 Contract Biotech API Manufacturing Market: Opportunities and Threats, 2015-2025
Table 8.3 Biotech API Manufacturing Services Market: STEP Analysis, 2015
Table 8.4 Selected EU-Approved Biosimilars: Manufacturers and Companies, 2015
Table 8.5 Approved Next-Generation Antibody Therapies, 2014
Table 10.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2015, 2017, 2019, 2021, 2023 and 2025
Table 10.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2015, 2017, 2019, 2021, 2023 and 2025

List of Figures
Figure 2.1 Steps for Biological Drug Manufacturing, 2015
Figure 2.2 Contract API Manufacturing: Market Shares by Sector (%), 2013
Figure 2.3 Future Trends in the Biotech API Manufacturing Market, 2015-2025
Figure 3.1 Contract Biotech API Manufacturing Services Market Forecast ($bn), 2014-2025
Figure 3.2 World Biologics Market: Revenue Forecast ($bn), 2015-2025
Figure 3.3 Contract Biotech API Manufacturing: Market Drivers, 2015-2025
Figure 3.4 Contract Biotech API Manufacturing: Market Restraints, 2015-2025
Figure 4.1 Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2014
Figure 4.2 Mammalian Cell Culture Submarket Forecast, 2015-2025
Figure 4.3 Mammalian Cell Culture Submarket: Drivers and Restraints, 2015-2025
Figure 4.4 Microbial Fermentation Submarket Forecast, 2015-2025
Figure 4.5 Microbial Fermentation Submarket: Drivers and Restraints, 2015
Figure 4.6 Two Year Forecast for Other Expression Systems Submarket, 2015-2025
Figure 5.1 US Biologics Clinical R&D Pipeline by Sector, 2013
Figure 5.2 Monoclonal Antibody Market: Contract API Revenues Forecast ($bn), 2014-2025
Figure 5.3 Vaccines Market: Contract API Revenues Forecast ($bn), 2014-2025
Figure 5.4 Insulin Therapies Market: Contract API Revenues Forecast ($bn), 2014-2025
Figure 5.5 Interferon Therapies Market: Contract API Revenues Forecast ($bn), 2014-2025
Figure 5.6 Growth Hormones Market: Contract API Revenues Forecast ($bn), 2014-2025
Figure 6.1 Contract Biotech API Manufacturing: Market Shares by Region (%), 2014
Figure 6.2 Contract Biotech API Manufacturing: Market Shares by Region (%), 2019
Figure 6.3 Contract Biotech API Manufacturing: Market Shares by Region (%), 2025
Figure 6.4 EU and Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), 2015-2025
Figure 6.5 EU Contract Biotech API Manufacturing: Leading National Revenue Shares (%), 2014
Figure 6.6 German Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.7 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.8 French Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.9 Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.10 Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.11 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.12 US Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.13 Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.14 Contract Biotech API Manufacturing Market: Emerging National Revenue Forecasts ($bn), 2014 and 2025
Figure 6.15 Biologics Market: Emerging Revenue Shares (%), 2014
Figure 6.16 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.17 Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.18 Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.19 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.20 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 6.21 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), 2014-2025
Figure 7.1 Leading Biotech API CMOs: Mammalian Cell Culture Manufacturing Scale, 2015
Figure 7.2 Leading Biotech API CMOs: Microbial Fermentation Manufacturing Scale, 2015
Figure 7.3 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2013-2014
Figure 7.4 Celltrion: Revenue ($bn), 2009-2014
Figure 7.5 DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2014
Figure 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), 2009-2014
Figure 8.1 Biosimilars Market Revenue Forecast ($bn), 2014, 2019, and 2025
Figure 10.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2015, 2017, 2019, 2021, 2023 and 2025
Figure 10.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2015, 2017, 2019, 2021, 2023 and 2025

【レポートのキーワード】

生物学的製剤、API(原薬)製造サービス、哺乳類細胞培養、微生物発酵、細胞発現、製薬

★調査レポート[生物学的製剤API(原薬)製造サービスの世界市場] ( Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025 / VGAIN5072209) 販売に関する免責事項
[生物学的製剤API(原薬)製造サービスの世界市場] ( Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025 / VGAIN5072209) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆